Compare stocks

BioGaia AB is a Swedish biotechnology company that specializes in the development and commercialization of probiotic products. The company's core business revolves around creating proprietary probiotic strains that are used to support digestive health. Notably, BioGaia's products are often formulated into dietary supplements, as well as being incorporated into infant formula and dairy products. Founded in 1990, BioGaia is headquartered in Stockholm, Sweden, and operates on a global scale, distributing its products in over 100 countries. The company is strategically positioned through its research collaborations and partnerships, enhancing its competitive strengths in the probiotic segment.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.